← Patent-cliff monitor small molecule NEXTSTELLIS DROSPIRENONE; ESTETROL
Loss of exclusivity October 2043 latest FDA-listed patent expiry
Drug detail Brand name NEXTSTELLIS Active ingredient DROSPIRENONE; ESTETROL Strength 3MG;14.2MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2021 Marketing status RX
Listed patents Patent Expires Type 12458649 October 2043 use U-3152 12233074 February 2043 product 11964055 June 2036 product 12427114 June 2036 product 11957694 June 2036 product 11793760 June 2036 product 7732430 January 2028 product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.